Benzinga.com

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Altimmune Inc. (NASDAQ: ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide. Patients had metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks. MASH is a ...

Did you know fatty liver disease can happen without alcohol and weight loss can reverse it? Doctor shares 5 liver facts

Non-alcoholic fatty liver disease is on the rise and mainly stems from metabolic dysfunction. Dr Sood shares five facts about ...
Benzinga.com

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

On Thursday, Altimmune, Inc. (NASDAQ:ALT) released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). MASH is a severe liver ...
Seeking Alpha

Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in ...

GAITHERSBURG, Md., June 05, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented new data on the potential anti-inflammatory and ...

Fatty liver disease is rising: 8 common NAFLD myths doctors want you to stop believing

Fatty liver disease sounds mild, almost harmless. That name alone pushes many people into denial. There is usually no pain, no dramatic symptom, and no daily disruption. So the condition stays ...